
Opinion|Videos|November 4, 2024
Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights
Panelists review available treatment options for recurrent endometrial cancer, discussing their typical treatment approaches and the factors influencing treatment selection. Panelists also address insights from the RUBY trial, its updates, and the expanded FDA indication for dostarlimab, including the implications of these developments on treatment strategies and the potential benefits and challenges of broader use in patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly review the available treatment options for recurrent endometrial cancer.
- What is your typical treatment approach for patients with recurrent endometrial cancer, and what factors drive your treatment selection?
- In which patients do you opt for single-agent immunotherapy (IO) vs chemotherapy + IO, and what is your underlying rationale?
- Talking points: RUBY trial, part 2 of RUBY trial, GY018, DUO-E
- Dostarlimab, durvalumab + carboplatin + paclitaxel +/- olaparib, pembrolizumab
- Briefly comment on recent data updates presented for the RUBY trial and offer insights into the expanded FDA indication for dostarlimab in endometrial cancer.
- Briefly comment on key takeaways from extended efficacy and safety data leading to the expanded approval.
- How does the expanded indication approved for dostarlimab impact your treatment approach for advanced or recurrent endometrial cancer?
- What are the potential benefits and challenges of using dostarlimab in a broader patient population?
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC
5


